Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04333706 |
|---|---|
| Brief Title: | A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER) |
| First Submitted : | April 1, 2020 |
| First Submitted that Met QC Criteria : | April 1, 2020 |
| First Posted : | April 3, 2020 |
| Last Update Submitted that Met QC Criteria : | January 16, 2024 |
| Last Update Posted : | January 18, 2024 |